This Week’s CGT News: Base Editing Takes Aim at Cholesterol - Takeaways - MDSpire

This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

  • June 1, 2026

  • 5 min

Share

  • 1

    VERVE-102 is a one-time base editing therapy that inactivates PCSK9, showing significant cholesterol reduction in a phase 1 study.

  • 2

    The therapy produced up to 88% reduction in PCSK9 and 62% reduction in LDL-C, with effects lasting over a year in some participants.

  • 3

    Eli Lilly acquired Engage Bio to enhance its genetic medicines portfolio with non-viral DNA delivery technologies.

  • 4

    Korecyte Bio is developing a tumour-activated CAR-T therapy platform aimed at improving treatment for solid cancers.

  • 5

    Scribe Therapeutics has received clearance for a first-in-human study of STX-1150, a CRISPR-based therapy targeting PCSK9.

Original Source(s)

This Week’s CGT News: Base Editing Takes Aim at Cholesterol

  • June 1, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Electroacupuncture alleviates myocardial ischemia-reperfusion injury by targeting and inhibiting NLRP3 inflammasome-mediated cardiomyocyte pyroptosis via serum exosomal miR-22-3p

HFpEF risk assessment using H2FPEF score in community-dwelling young Hispanic adults